Polymers · 2025
Preliminary Study on the Development of a Biodegradable Functional Nasal Packing Material.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Dong Hoon, So EunA, Mustafa Faizan E, Jeong Jae-Ho, Lee Bong-Kee
Аннотация
INTRODUCTION: Functional endoscopic sinus surgery is commonly performed to treat paranasal sinus diseases, often necessitating nasal packing to control bleeding and aid healing. However, current materials can cause discomfort or lack adequate antibacterial properties. This study aimed to develop a biodegradable, biocompatible nasal packing material by combining polyvinyl alcohol (PVA) and carbon dots (CDs), and to evaluate its antibacterial activity and tissue compatibility.
MATERIALS AND METHODS: Electrospun nanofiber membranes were fabricated using PVA and biomass-derived CDs. Antibacterial efficacy of nasal packing variants (PVA, PVA-chitosan [CS], PVA-CS-CDs-1 mL, and PVA-CS-CDs-2 mL) was assessed using the Kirby-Bauer disk diffusion method against Escherichia coli, Salmonella spp., and Staphylococcus aureus. The in vivo biocompatibility was evaluated via histological analysis following implantation into the nasal cavity of mice.
RESULTS: All materials demonstrated antibacterial activity, with PVA-CS-CDs-2 mL showing the largest inhibition zones. Histological examination revealed minimal epithelial damage and no inflammation, with PVA-CS-CDs-2 mL yielding the most favorable tissue response.
CONCLUSION: The PVA-CS-CDs composite demonstrates potential as a biocompatible, antibacterial nasal packing material. Further studies are warranted to validate its long-term clinical utility.
MATERIALS AND METHODS: Electrospun nanofiber membranes were fabricated using PVA and biomass-derived CDs. Antibacterial efficacy of nasal packing variants (PVA, PVA-chitosan [CS], PVA-CS-CDs-1 mL, and PVA-CS-CDs-2 mL) was assessed using the Kirby-Bauer disk diffusion method against Escherichia coli, Salmonella spp., and Staphylococcus aureus. The in vivo biocompatibility was evaluated via histological analysis following implantation into the nasal cavity of mice.
RESULTS: All materials demonstrated antibacterial activity, with PVA-CS-CDs-2 mL showing the largest inhibition zones. Histological examination revealed minimal epithelial damage and no inflammation, with PVA-CS-CDs-2 mL yielding the most favorable tissue response.
CONCLUSION: The PVA-CS-CDs composite demonstrates potential as a biocompatible, antibacterial nasal packing material. Further studies are warranted to validate its long-term clinical utility.